Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma

Regulation and Importance of the PI3K/Akt/mTOR Signaling Pathway in Hematologic Malignancies

(2012) Kiyotaka Kawauchi et al.   Anti-Cancer Agents in Medicinal Chemistry

Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

(2010) Sean J. Whittaker et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase I Trial of Enzastaurin in Patients with Recurrent Gliomas

(2009) T. N. Kreisl et al.   CLINICAL CANCER RESEARCH

Exploitation of protein kinase C: A useful target for cancer therapy

(2008) Ashhar S. Ali et al.   CANCER TREATMENT REVIEWS

Potential Role of PKC Inhibitors in the Treatment of Hematological Malignancies

(2008) Carlo Mischiati et al.   CURRENT PHARMACEUTICAL DESIGN

A pilot quality-of-life instrument for pruritus

(2008) Nisha S. Desai et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma

(2007) F. Morschhauser et al.   ANNALS OF ONCOLOGY